News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40,256 Results
Type
Article (2576)
Company Profile (45)
Press Release (37634)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (14254)
Career Advice (78)
Deals (2118)
Drug Delivery (9)
Drug Development (4152)
Employer Resources (10)
FDA (444)
Job Trends (784)
News (20357)
Policy (1058)
Tag
Academia (146)
Allergies (7)
Alliances (3497)
ALS (6)
Alzheimer's disease (59)
Antibody-drug conjugate (ADC) (27)
Approvals (447)
Artificial intelligence (31)
Autoimmune disease (8)
Automation (2)
Bankruptcy (12)
Best Places to Work (478)
BIOSECURE Act (2)
Biosimilars (16)
Biotechnology (29)
Bladder cancer (8)
Brain cancer (7)
Breast cancer (44)
Cancer (324)
Cardiovascular disease (10)
Career advice (66)
Career pathing (1)
CAR-T (31)
CDC (1)
Cell therapy (81)
Cervical cancer (2)
Clinical research (3445)
Collaboration (199)
Company closure (2)
Compensation (104)
COVID-19 (185)
CRISPR (11)
C-suite (112)
Cystic fibrosis (7)
Data (418)
Denatured (6)
Depression (11)
Diabetes (17)
Diagnostics (489)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (36)
Drug pricing (10)
Duchenne muscular dystrophy (40)
Earnings (4530)
Editorial (5)
Employer branding (1)
Employer resources (8)
Events (6408)
Executive appointments (134)
FDA (589)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (167)
Gene editing (32)
Generative AI (1)
Gene therapy (55)
GLP-1 (63)
Government (158)
Guidances (24)
Healthcare (710)
HIV (1)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (34)
Immuno-oncology (14)
Indications (4)
Infectious disease (197)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (25)
Interviews (7)
IPO (1002)
IRA (7)
Job creations (293)
Job search strategy (62)
JPM (4)
Kidney cancer (6)
Labor market (11)
Layoffs (51)
Leadership (3)
Legal (215)
Liver cancer (6)
Longevity (1)
Lung cancer (28)
Lymphoma (12)
Machine learning (3)
Management (4)
Manufacturing (52)
MASH (14)
Medical device (323)
Medtech (324)
Mergers & acquisitions (1231)
Metabolic disorders (72)
Multiple sclerosis (22)
Neurodegenerative disease (27)
Neuropsychiatric disorders (10)
Neuroscience (164)
NextGen: Class of 2026 (353)
Non-profit (155)
Now hiring (11)
Obesity (32)
Opinion (17)
Ovarian cancer (17)
Pain (24)
Pancreatic cancer (21)
Parkinson's disease (11)
Partnered (4)
Patents (53)
Patient recruitment (25)
Peanut (1)
People (5901)
Pharmaceutical (5)
Phase 1 (1475)
Phase 2 (1703)
Phase 3 (920)
Pipeline (390)
Policy (16)
Postmarket research (31)
Preclinical (641)
Press Release (2)
Prostate cancer (7)
Psychedelics (3)
Radiopharmaceuticals (14)
Rare diseases (62)
Real estate (427)
Recruiting (5)
Regulatory (917)
Reports (7)
Research institute (154)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (5)
RSV (1)
Schizophrenia (16)
Series A (46)
Series B (20)
Service/supplier (2)
Sickle cell disease (3)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (499)
Stomach cancer (2)
Supply chain (4)
Tariffs (2)
The Weekly (3)
Vaccines (52)
Venture capital (15)
Weight loss (21)
Women's health (10)
Worklife (1)
Date
Last 7 days (39)
Last 30 days (137)
Last 365 days (2412)
2026 (211)
2025 (2439)
2024 (2616)
2023 (2861)
2022 (3766)
2021 (4061)
2020 (3482)
2019 (2069)
2018 (1571)
2017 (1810)
2016 (1648)
2015 (1855)
2014 (1371)
2013 (1192)
2012 (1398)
2011 (1335)
2010 (1182)
Location
Africa (44)
Alabama (3)
Arizona (18)
Asia (1952)
Australia (308)
California (1601)
Canada (243)
China (80)
Colorado (54)
Connecticut (16)
Delaware (5)
Europe (4030)
Florida (64)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (21)
India (2)
Indiana (60)
Japan (17)
Kansas (14)
Kentucky (1)
Maryland (48)
Massachusetts (568)
Michigan (14)
Minnesota (22)
Mississippi (1)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (133)
New York (81)
North Carolina (131)
Northern California (781)
Ohio (44)
Oklahoma (2)
Oregon (6)
Pennsylvania (109)
Puerto Rico (1)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (652)
Tennessee (4)
Texas (152)
United States (3203)
Utah (5)
Virginia (11)
Washington D.C. (3)
Washington State (95)
West Virginia (1)
Wisconsin (13)
40,256 Results for "cogent biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA
Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next year after what Leerink said was “the first positive trial in this disease in over a decade.”
November 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
January 27, 2026
·
5 min read
Press Releases
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
January 12, 2026
·
8 min read
Press Releases
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
1 min read
Press Releases
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
December 30, 2025
·
5 min read
Press Releases
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
January 20, 2026
·
5 min read
Press Releases
Cogent Biosciences Announces Participation in the 2025 Jefferies Global Healthcare Conference
November 17, 2025
·
1 min read
Press Releases
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
October 21, 2025
·
5 min read
Press Releases
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 8, 2025
·
8 min read
Press Releases
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
November 4, 2025
·
9 min read
1 of 4,026
Next
